Can a diabetes pill shield hearts and kidneys after ICU?
NCT ID NCT07025629
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether the drug dapagliflozin (Farxiga) can reduce deaths and heart or kidney problems in people leaving the intensive care unit (ICU). About 600 adults who needed a breathing machine or blood pressure support will take either the drug or a placebo daily for 12 months. The goal is to see if this simple pill can improve long-term outcomes for ICU survivors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dapagliflozin (Farxiga) 10 mg oral tablet
- What this could lead to
- If it works, this could provide a simple daily pill to protect the heart and kidneys of people leaving the ICU, potentially reducing deaths and hospital readmissions.
- What could go wrong
- This is a phase 3 trial, but it is still testing a new use for an existing drug. The results may not apply to all ICU survivors, and side effects like dehydration or infections are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Saint Louis
RECRUITINGParis, 75010, France
-
Saint Louis Hospital
NOT_YET_RECRUITINGParis, 75010, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk